149 related articles for article (PubMed ID: 28333018)
1. Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer.
Yoshioka Y; Kotsuma T; Komiya A; Kariya S; Konishi K; Nonomura N; Ogawa K; Tanaka E; Nishimura K; Fujiuchi Y; Kitamura H; Yamagami T; Yamasaki I; Nishimura K; Teshima T; Nakamura K; Itami J
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):952-961. PubMed ID: 28333018
[TBL] [Abstract][Full Text] [Related]
2. High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up.
Yoshioka Y; Suzuki O; Isohashi F; Seo Y; Okubo H; Yamaguchi H; Oda M; Otani Y; Sumida I; Uemura M; Fujita K; Nagahara A; Ujike T; Kawashima A; Yoshida K; Yamazaki H; Nonomura N; Ogawa K
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):675-82. PubMed ID: 26238951
[TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
4. 125Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up.
Sekiguchi A; Ishiyama H; Satoh T; Tabata K; Komori S; Tsumura H; Kawakami S; Soda I; Iwamura M; Hayakawa K
J Radiat Res; 2014 Mar; 55(2):328-33. PubMed ID: 24105711
[TBL] [Abstract][Full Text] [Related]
5. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.
Ciezki JP; Weller M; Reddy CA; Kittel J; Singh H; Tendulkar R; Stephans KL; Ulchaker J; Angermeier K; Stephenson A; Campbell S; Haber GP; Klein EA
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):962-975. PubMed ID: 28333019
[TBL] [Abstract][Full Text] [Related]
6. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
[TBL] [Abstract][Full Text] [Related]
7. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
8. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
9. High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results.
Hauswald H; Kamrava MR; Fallon JM; Wang PC; Park SJ; Van T; Borja L; Steinberg ML; Demanes DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):667-74. PubMed ID: 26443877
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three moderate fractionated schedules employed in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2018 Nov; 129(2):370-376. PubMed ID: 30190166
[TBL] [Abstract][Full Text] [Related]
11. High dose rate brachytherapy for prostate cancer: A prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions.
Nagore G; Lopez Guerra JL; Krumina E; Lagos M; Ovalles B; Miró A; Beltran L; Gómez E; Praena-Fernandez JM; Del Campo ER; Azinovic I; Gomez-Iturriaga A
Radiother Oncol; 2018 May; 127(2):219-224. PubMed ID: 29625808
[TBL] [Abstract][Full Text] [Related]
12. Reirradiation of Prostate Cancer Local Failures After Previous Curative Radiation Therapy: Long-Term Outcome and Tolerance.
Zilli T; Benz E; Dipasquale G; Rouzaud M; Miralbell R
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):318-322. PubMed ID: 27475672
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.
Kotecha R; Yamada Y; Pei X; Kollmeier MA; Cox B; Cohen GN; Zaider M; Zelefsky MJ
Brachytherapy; 2013; 12(1):44-9. PubMed ID: 22831750
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
16. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
[TBL] [Abstract][Full Text] [Related]
17. High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes.
Chao M; Bolton D; Lim Joon D; Chan Y; Lawrentschuk N; Ho H; Spencer S; Wasiak J; Guerrieri M; Ow D; Troy A; Pham T; Sengupta S; Tan A; McMillan K; Koufogiannis G; Foroudi F; Ng M; Khoo V
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):415-421. PubMed ID: 30908894
[TBL] [Abstract][Full Text] [Related]
18. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer.
Strouthos I; Chatzikonstantinou G; Zamboglou N; Milickovic N; Papaioannou S; Bon D; Zamboglou C; Rödel C; Baltas D; Tselis N
Radiother Oncol; 2018 Aug; 128(2):301-307. PubMed ID: 29764692
[TBL] [Abstract][Full Text] [Related]
19. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
